Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis
Low concentrations of insulin-like growth factor (IGF) binding protein-1 (IGFBP1) are associated with insulin resistance, diabetes, and cardiovascular disease. We investigated whether increasing IGFBP1 levels can prevent the development of these disorders. Metabolic and vascular phenotype were examined in response to human IGFBP1 overexpression in mice with diet-induced obesity, mice heterozygous for deletion of insulin receptors (IR +/-), and ApoE -/- mice. Direct effects of human (h) IGFBP1 on nitric oxide (NO) generation and cellular signaling were studied in isolated vessels and in human endothelial cells. IGFBP1 circulating levels were markedly suppressed in dietary-induced obese mice. Overexpression of hIGFBP1 in obese mice reduced blood pressure, improved insulin sensitivity, and increased insulin-stimulated NO generation. In nonobese IR +/-mice, overexpression of hIGFBP1 reduced blood pressure and improved insulin-stimulated NO generation. hIGFBP1 induced vasodilatation independently of IGF and increased endothelial NO synthase (eNOS) activity in arterial segments ex vivo, while in endothelial cells, hIGFBP1 increased eNOS Ser 1177 phosphorylation via phosphatidylinositol 3-kinase signaling. Finally, in ApoE -/- mice, overexpression of hIGFBP1 reduced atherosclerosis. These favorable effects of hIGFBP1 on insulin sensitivity, blood pressure, NO production, and atherosclerosis suggest that increasing IGFBP1 concentration may be a novel approach to prevent cardiovascular disease in the setting of insulin resistance and diabetes.
915-924
Rajwani, Adil
ca0b632b-3739-4aa6-917b-51350cfe5b6a
Ezzat, Vivienne
dfebd808-3f5d-4dc0-bd98-c0da879bfab5
Smith, Jessica
cfcf3d7a-a75d-4970-b46d-2ad871ba11f5
Yuldasheva, Nadira Y.
d08c7562-4bab-4dbd-a96a-fe596dde0065
Duncan, Edward R.
c2ef9350-e625-498f-9ce3-65852e8ae9ce
Gage, Matthew
ac4f91ec-177b-4d77-8252-7cbc41b5272e
Cubbon, Richard M.
a50d05e8-befc-4f5f-aeef-17d70faedf07
Kahn, Matthew B.
5402645f-4559-4f33-ad5b-9a1acef1475d
Imrie, Helen
2a974160-63a2-49b7-b88b-1dd8ce2fe6db
Abbas, Afroze
312c99dc-f6c6-40ed-824b-2fca92bede82
Viswambharan, Hema
0c09dc96-be38-492f-8cb6-c462139089a2
Aziz, Amir
4c176c9b-3946-4150-8947-3ec5ac50121b
Sukumar, Piruthivi
fe865bd6-972a-4b98-988c-81435198e957
Vidal-Puig, Antonio
7d46d380-1b9d-40cb-90a3-72679e143036
Sethi, Jaswinder K.
923f1a81-91e4-46cd-8853-bb4a979f5a85
Xuan, Shouhong
85766a57-2ab4-473a-a02b-d12e15f81fb0
Shah, Ajay M.
20c6e370-6389-46f5-9673-c68712df43a1
Grant, Peter J.
48c196cb-3754-449b-9142-292f202dc5f5
Porter, Karen E.
49e30839-16a5-4f82-b851-505d8039cf57
Kearney, Mark T.
f536cadd-e1e5-480f-bd63-3c749e9de2bc
Wheatcroft, Stephen B.
c530177b-e404-4c7b-9f14-c2ccba5bc1f7
April 2012
Rajwani, Adil
ca0b632b-3739-4aa6-917b-51350cfe5b6a
Ezzat, Vivienne
dfebd808-3f5d-4dc0-bd98-c0da879bfab5
Smith, Jessica
cfcf3d7a-a75d-4970-b46d-2ad871ba11f5
Yuldasheva, Nadira Y.
d08c7562-4bab-4dbd-a96a-fe596dde0065
Duncan, Edward R.
c2ef9350-e625-498f-9ce3-65852e8ae9ce
Gage, Matthew
ac4f91ec-177b-4d77-8252-7cbc41b5272e
Cubbon, Richard M.
a50d05e8-befc-4f5f-aeef-17d70faedf07
Kahn, Matthew B.
5402645f-4559-4f33-ad5b-9a1acef1475d
Imrie, Helen
2a974160-63a2-49b7-b88b-1dd8ce2fe6db
Abbas, Afroze
312c99dc-f6c6-40ed-824b-2fca92bede82
Viswambharan, Hema
0c09dc96-be38-492f-8cb6-c462139089a2
Aziz, Amir
4c176c9b-3946-4150-8947-3ec5ac50121b
Sukumar, Piruthivi
fe865bd6-972a-4b98-988c-81435198e957
Vidal-Puig, Antonio
7d46d380-1b9d-40cb-90a3-72679e143036
Sethi, Jaswinder K.
923f1a81-91e4-46cd-8853-bb4a979f5a85
Xuan, Shouhong
85766a57-2ab4-473a-a02b-d12e15f81fb0
Shah, Ajay M.
20c6e370-6389-46f5-9673-c68712df43a1
Grant, Peter J.
48c196cb-3754-449b-9142-292f202dc5f5
Porter, Karen E.
49e30839-16a5-4f82-b851-505d8039cf57
Kearney, Mark T.
f536cadd-e1e5-480f-bd63-3c749e9de2bc
Wheatcroft, Stephen B.
c530177b-e404-4c7b-9f14-c2ccba5bc1f7
Rajwani, Adil, Ezzat, Vivienne, Smith, Jessica, Yuldasheva, Nadira Y., Duncan, Edward R., Gage, Matthew, Cubbon, Richard M., Kahn, Matthew B., Imrie, Helen, Abbas, Afroze, Viswambharan, Hema, Aziz, Amir, Sukumar, Piruthivi, Vidal-Puig, Antonio, Sethi, Jaswinder K., Xuan, Shouhong, Shah, Ajay M., Grant, Peter J., Porter, Karen E., Kearney, Mark T. and Wheatcroft, Stephen B.
(2012)
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis.
Diabetes, 61 (4), .
(doi:10.2337/db11-0963).
Abstract
Low concentrations of insulin-like growth factor (IGF) binding protein-1 (IGFBP1) are associated with insulin resistance, diabetes, and cardiovascular disease. We investigated whether increasing IGFBP1 levels can prevent the development of these disorders. Metabolic and vascular phenotype were examined in response to human IGFBP1 overexpression in mice with diet-induced obesity, mice heterozygous for deletion of insulin receptors (IR +/-), and ApoE -/- mice. Direct effects of human (h) IGFBP1 on nitric oxide (NO) generation and cellular signaling were studied in isolated vessels and in human endothelial cells. IGFBP1 circulating levels were markedly suppressed in dietary-induced obese mice. Overexpression of hIGFBP1 in obese mice reduced blood pressure, improved insulin sensitivity, and increased insulin-stimulated NO generation. In nonobese IR +/-mice, overexpression of hIGFBP1 reduced blood pressure and improved insulin-stimulated NO generation. hIGFBP1 induced vasodilatation independently of IGF and increased endothelial NO synthase (eNOS) activity in arterial segments ex vivo, while in endothelial cells, hIGFBP1 increased eNOS Ser 1177 phosphorylation via phosphatidylinositol 3-kinase signaling. Finally, in ApoE -/- mice, overexpression of hIGFBP1 reduced atherosclerosis. These favorable effects of hIGFBP1 on insulin sensitivity, blood pressure, NO production, and atherosclerosis suggest that increasing IGFBP1 concentration may be a novel approach to prevent cardiovascular disease in the setting of insulin resistance and diabetes.
This record has no associated files available for download.
More information
Accepted/In Press date: 29 December 2011
e-pub ahead of print date: 22 February 2012
Published date: April 2012
Identifiers
Local EPrints ID: 415311
URI: http://eprints.soton.ac.uk/id/eprint/415311
ISSN: 0012-1797
PURE UUID: 95d20d78-3d9a-4aa9-a5c4-5c0ca357f696
Catalogue record
Date deposited: 07 Nov 2017 17:30
Last modified: 16 Mar 2024 04:31
Export record
Altmetrics
Contributors
Author:
Adil Rajwani
Author:
Vivienne Ezzat
Author:
Jessica Smith
Author:
Nadira Y. Yuldasheva
Author:
Edward R. Duncan
Author:
Matthew Gage
Author:
Richard M. Cubbon
Author:
Matthew B. Kahn
Author:
Helen Imrie
Author:
Afroze Abbas
Author:
Hema Viswambharan
Author:
Amir Aziz
Author:
Piruthivi Sukumar
Author:
Antonio Vidal-Puig
Author:
Shouhong Xuan
Author:
Ajay M. Shah
Author:
Peter J. Grant
Author:
Karen E. Porter
Author:
Mark T. Kearney
Author:
Stephen B. Wheatcroft
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics